Sartorius Stedim Biotech S.A. (DIM)

Basic

  • Market Cap

    €18.62B

  • EV

    €22.33B

  • Shares Out

    92.16M

  • Revenue

    €2,958.7M

  • Employees

    10,849

Margins

  • Gross

    49.12%

  • EBITDA

    29.71%

  • Operating

    23.22%

  • Pre-Tax

    19.75%

  • Net

    15.56%

  • FCF

    3.81%

Returns (5Yr Avg)

  • ROA

    14.11%

  • ROE

    27.03%

  • ROCE

    29.39%

  • ROIC

    18.48%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    €229.17

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    €32.11

  • Earnings (Dil)

    €5

  • FCF

    €1.22

  • Book Value

    €28.27

Growth (CAGR)

  • Rev 3Yr

    19.28%

  • Rev 5Yr

    20.34%

  • Rev 10Yr

    17.96%

  • Dil EPS 3Yr

    15.66%

  • Dil EPS 5Yr

    20.01%

  • Dil EPS 10Yr

    21.98%

  • Rev Fwd 2Yr

    -5.62%

  • EBITDA Fwd 2Yr

    -11.19%

  • EPS Fwd 2Yr

    -23.14%

  • EPS LT Growth Est

    23%

Dividends

  • Yield

    —

  • Payout

    15.15%

  • DPS

    €1.44

  • DPS Growth 3Yr

    61.79%

  • DPS Growth 5Yr

    25.64%

  • DPS Growth 10Yr

    22.89%

  • DPS Growth Fwd 2Yr

    -19.68%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Total Revenues

1,212.2

1,440.6

1,910.1

2,887.0

3,492.7

2,958.7

Total Revenues % Chg.

12.1%

18.8%

32.6%

51.1%

21.0%

-12.5%

Cost of Goods Sold, Total

582.6

692.3

906.8

1,334.0

1,658.2

1,505.3

Gross Profit

629.6

748.3

1,003.3

1,553.0

1,834.5

1,453.4

Selling General & Admin Expenses, Total

282.9

317.6

391.8

531.9

601.6

598.3

R&D Expenses

60.6

79.2

84.5

110.5

132.4

131.0

Other Operating Expenses

-0.8

3.5

23.9

-9.6

-15.9

37.0

Other Operating Expenses, Total

342.7

400.4

500.2

632.8

718.1

766.3

Operating Income

286.9

347.9

503.1

920.2

1,116.4

687.1

Interest Expense, Total

-3.3

-3.9

-6.5

-10.2

-18.2

-134.5

Interest And Investment Income

0.4

0.3

0.5

0.3

0.5

—

Net Interest Expenses

-3.0

-3.5

-6.0

-9.9

-17.7

-134.5

Currency Exchange Gains (Loss)

-0.0

-11.7

-14.7

12.3

-32.5

-32.5

Other Non Operating Income (Expenses)

-12.1

1.5

1.1

-37.1

-38.8

-38.9

EBT, Excl. Unusual Items

271.8

334.2

483.6

885.5

1,027.4

481.2

Restructuring Charges

—

—

—

—

—

—

Merger & Related Restructuring Charges

—

-0.3

-4.3

-20.3

-13.7

-13.7

Other Unusual Items

12.7

-16.5

-18.6

-218.5

116.7

116.7

EBT, Incl. Unusual Items

284.5

317.4

460.7

646.7

1,130.4

584.2

Income Tax Expense

74.6

81.4

122.1

232.4

250.5

119.8

Earnings From Continuing Operations

210.0

236.0

338.6

414.3

879.9

464.4

Minority Interest

-1.9

-1.5

-2.7

0.1

-3.8

-4.0

Net Income

208.1

234.5

335.9

414.4

876.1

460.4

Net Income to Common Incl Extra Items

208.1

234.5

335.9

414.4

876.1

460.4

Net Income to Common Excl. Extra Items

208.1

234.5

335.9

414.4

876.1

460.4

Total Shares Outstanding

92.2

92.2

92.2

92.2

92.2

91.8

Weighted Avg. Shares Outstanding

92.2

92.2

92.2

92.2

92.2

92.1

Weighted Avg. Shares Outstanding Dil

92.2

92.2

92.2

92.2

92.2

92.1

EPS

2.3

2.5

3.6

4.5

9.5

5.0

EPS Diluted

2.3

2.5

3.6

4.5

9.5

5.0

EBITDA

342.0

401.5

577.3

1,031.4

1,258.9

879.1